Stepwise development of structure–activity relationship of diverse PARP-1 inhibitors through comparative and validated in silico modeling techniques and molecular dynamics simulation

References

• Adhikari, N., Halder, A. K., Mondal, C., & Jha, T. (2013). Exploring structural requirements of aurone derivatives as antimalarials by validated DFT-based QSAR, HQSAR, and COMFA–COMSIA approach. Medicinal Chemistry Research, 22, 6029–6045. doi:10.1007/s00044-013-0590-810.1007/s00044-013-0590-8
   Web of Science ®Google Scholar
• Alarcon de la Lastra, C., Villegas, I., & Sanchez-Fidalgo, S. (2007). Poly(ADP-ribose)polymerase inhibitors: New pharmacological functions and potential clinical implications. Current Pharmaceutical Design, 13, 933–962. doi:10.2174/13816120778041424110.2174/138161207780414241
   PubMed Web of Science ®Google Scholar
• Ame, J. C., Spenlehauer, C., & Murcia, G. (2004). The PARP superfamily. BioEssays, 26, 882–893. doi:10.1002/bies.2008510.1002/(ISSN)1521-1878
   PubMed Web of Science ®Google Scholar
• An, Y., Sherman, W., & Dixon, S. L. (2013). Kernel-based partial least squares: Application to fingerprint-based QSAR with model visualization. Journal of Chemical Information and Modeling, 53, 2312–2321. doi:10.1021/ci400250c10.1021/ci400250c
   PubMed Web of Science ®Google Scholar
• Basak, S. C. (1999). Information theoretic indices of neighborhood complexity and their applications. In J. Devillers & A. T. Balaban (Eds.), Bibliography topological indices and related descriptors in QSAR and QSPR (pp. 563–593). Amsterdam: Gordon and Breach Science Publishers.
   Google Scholar
• Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., … Bourne, P. E. (2000). The Protein Data Bank. Nucleic Acids Research, 28, 235–242. doi:10.1093/nar/28.1.23510.1093/nar/28.1.235
   PubMed Web of Science ®Google Scholar
• Bowers, K. J., Chow, E., Xu, H., Dror, R. O., Eastwood, M. P., Gregersen, B. A., … Shaw, D. E. (2006). Scalable algorithms for molecular dynamics simulations on commodity clusters. In Proceedings of the ACM/IEEE Conference on Supercomputing (SC06), Tampa, Florida, November 11–17.
   Google Scholar
• Branca, D., Cerretani, M., Jones, P., Koch, U., Orvieto, F., Palumbi, M. C, …Mugarlia, E. (2009). Identification of aminoethyl pyrrolodihydroisoquinolinones as novel poly(ADP-ribose) polymerase-1 inhibitors. Bioorganic & Medicinal Chemistry Letters, 19, 4042–4045. doi:10.1016/j.bmcl.2009.06.031
   PubMed Web of Science ®Google Scholar
• Canvas Version 1.8. (2013). New York, NY: Schrödinger, LLC.
   Google Scholar
• Costantino, G., Macchiarulo, A., Camaioni, E., & Pellicciari, R. (2001). Modeling of poly (ADP-ribose) polymerase (PARP) inhibitors. Docking of ligands and quantitative structure-activity relationship analysis. Journal of Medicinal Chemistry, 44, 3786–3794. doi:10.1021/jm010116l10.1021/jm010116l
   PubMed Web of Science ®Google Scholar
• Das, D., Koh, Y., Tojo, Y., Ghosh, A. K., & Mitsuya, H. (2009). Prediction of potency of protease inhibitors using free energy simulations with polarizable quantum mechanics-based ligand charges and a hybrid water model. Journal of Chemical Information and Modeling, 49, 2851–2862. doi:10.1021/ci900320p10.1021/ci900320p
   PubMed Web of Science ®Google Scholar
• Davar, D., Beumer, J. H., Hamieh, L., & Tawbi, H. (2012). Role of PARP inhibitors in cancer biology and therapy. Current Medicinal Chemistry, 19, 3907–3921. doi:10.2174/09298671280200246410.2174/092986712802002464
   PubMed Web of Science ®Google Scholar
• Debnath, A. K. (2001). Quantitative structure-activity relationship (QSAR) paradigms Hansch era to new millennium. Mini Reviews in Medicinal Chemistry, 1, 187–195. doi:10.2174/138955701340706110.2174/1389557013407061
   PubMedGoogle Scholar
• Discovery Studio 3.0. (2011). San Diego, CA: Accelrys.
   Google Scholar
• Dixon, S. L., Smondyrev, A. M., Knoll, E. H., Rao, S. N., Shaw, D. E., & Friesner, R. A. (2006). PHASE: A new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. Journal of Computer Aided Molecular Design, 20, 647–671. doi:10.1007/s10822-006-9087-610.1007/s10822-006-9087-6
   PubMed Web of Science ®Google Scholar
• DRAGON Web version 2.1. (2000). Milano Chemometrics and QSAR Research group.
   Google Scholar
• Eriksson, L., Jaworska, J., Worth, A. P., Cronin, M. T., McDowell, R. M., & Gramatica, P. (2003). Methods for reliability and uncertainty assessment and for applicability evaluations of classification- and regression-based QSARs. Environmental Health Perspective, 111, 1361–1375. doi:10.1289/ehp.575810.1289/ehp.5758
   PubMed Web of Science ®Google Scholar
• Ferrigno, F., Branca, D., Kinzel, O., Lillini, S., Bufi, L. L., Monteagudo, E., … Jones, P. (2010). Development of substituted 6-[4-fluoro-3-(piperazin-1-ylcarbonyl)benzyl]-4,5-dimethylpyridazin-3(2H)-ones as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors active in BRCA deficient cells. Bioorganic & Medicinal Chemistry Letters, 20, 1100–1105. doi:10.1016/j.bmcl.2009.11.087
   PubMed Web of Science ®Google Scholar
• Field-Based QSAR, Version 2013-3. (2013). New York, NY: Schrödinger, LLC.
   Google Scholar
• Franke, R. (1984). The theoretical drug design methods. Amsterdam: Elsevier.
   Google Scholar
• Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Maint, D. T., … Shenkin, P. S. (2004). Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. Journal of Medicinal Chemistry, 25, 1713–1749. doi:10.1021/jm0306430
   Web of Science ®Google Scholar
• Galvez, J., Garcia, R., Salabert, M. T., & Soler, R. (1994). Charge indexes. New topological descriptors. Journal of Chemical Information and Computer Science, 34, 520–525. doi:10.1021/ci00019a00810.1021/ci00019a008
   Google Scholar
• Galvez, J., Garcia-Domenech, R., de Julian-Ortiz, J. V., & Soler, R. (1995). Topological approach to drug design. Journal of Chemical Information and Computer Science, 35, 272–284. doi:10.1021/ci00024a01710.1021/ci00024a017
   PubMedGoogle Scholar
• Gandhi, V. B., Luo, Y., Liu, X., Shi, Y., Klinghofer, V., Johnson, E. F., … Zhu, G. D. (2010). Discovery and SAR of substituted 3-oxoisoindoline-4-carboxamides as potent inhibitors of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer. Bioorganic & Medicinal Chemistry Letters, 20, 1023–1026. doi:10.1016/j.bmcl.2009.12.042
   PubMed Web of Science ®Google Scholar
• Gangloff, A. R., Brown, J., de Jong, R., Dougan, D. R., Hixon, C. E., Grimshaw, M., … Vu, P. (2013). Discovery of novel benzo[b][1,4]oxazin-3(4H)-ones as poly(ADP-ribose)polymerase inhibitors. Bioorganic & Medicinal Chemistry Letters, 23, 4501–4505. doi:10.1016/j.bmcl.2013.06.055
   PubMed Web of Science ®Google Scholar
• Garber, K. (2013). PARP inhibitors bounce back. Nature Reviews Drug Discovery, 12, 725–727. doi:10.1038/nrd414710.1038/nrd4147
   PubMed Web of Science ®Google Scholar
• Golbraikh, A., & Tropsha, A. (2002). Beware of q2!. Journal of Molecular Graphics and Modeling, 20, 269–276. doi:10.1016/S1093-3263(01)00123-110.1016/S1093-3263(01)00123-1
   PubMed Web of Science ®Google Scholar
• Goodford, P. J. (1985). A computational procedure for determining energetically favourable binding sites on biologically important macromolecules. Journal of Medicinal Chemistry, 28, 849–857. doi:10.1021/jm00145a00210.1021/jm00145a002
   PubMed Web of Science ®Google Scholar
• Halder, A. K., Adhikari, N., & Jha, T. (2010). Structural findings of 2-Phenylindole-3-carbaldehyde derivatives for antimitotic activity by FA-sMLR QSAR analysis. Chemical Biology & Drug Design, 75, 204–213. doi:10.1111/j.1747-0285.2009.00927.x
   PubMed Web of Science ®Google Scholar
• Halder, A. K., & Jha, T. (2010). Validated predictive QSAR modeling of N-aryl-oxazolidinone-5-carboxamides for anti-HIV protease activity. Bioorganic & Medicinal Chemistry Letters, 20, 6082–6087. doi:10.1016/j.bmcl.2010.08.050
   PubMed Web of Science ®Google Scholar
• Halder, A. K., Saha, A., & Jha, T. (2013a). Exploring QSAR and pharmacophore mapping of structurally diverse selective matrix metalloproteinase-2 inhibitors. Journal of Pharmacy and Pharmacology, 65, 1541–1554. doi:10.1111/jphp.1213310.1111/jphp.2013.65.issue-10
   PubMed Web of Science ®Google Scholar
• Halder, A. K., Saha, A., & Jha, T. (2013b). Exploration of structural and physicochemical requirements and search of virtual hits for aminopeptidase N inhibitors. Molecular Diversity, 17, 123–137. doi:10.1007/s11030-013-9422-510.1007/s11030-013-9422-5
   PubMed Web of Science ®Google Scholar
• Halder, A. K., Saha, A., & Jha, T. (2013c). The role of 3D pharmacophore mapping based virtual screening for identification of novel anticancer agents: An overview. Current Topics in Medicinal Chemistry, 13, 1098–1126. doi:10.2174/156802661131309000910.2174/1568026611313090009
   PubMed Web of Science ®Google Scholar
• Halgren, T. A., Murphy, R. B., Friesner, R. A., Beard, H. S., Frye, L. L., Pollard, W. T., & Banks, J. L. (2004). Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. Journal of Medicinal Chemistry, 51, 69–82. doi:10.1021/jm030644s
   Web of Science ®Google Scholar
• Horvath, E. M., & Szabo, C. (2007). Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: An update. Drug News Perspective, 20, 171–181. doi:10.1358/dnp.2007.20.3.109209810.1358/dnp.2007.20.3.1092098
   PubMed Web of Science ®Google Scholar
• Huang, N., Scoichet, B. K., & Irwin, J. J. (2006). Benchmarking sets for molecular docking. Journal of Medicinal Chemistry, 49, 6789–6801. doi:10.1021/jm060835610.1021/jm0608356
   PubMed Web of Science ®Google Scholar
• Huber, A., Bai, P., de Murcia, J. M., & de Murcia, G. (2004). PARP-1, PARP-2 and ATM in the DNA damage response: Functional synergy in mouse development. DNA Repair, 3, 1103–1108. doi:10.1016/j.dnarep.2004.06.00210.1016/j.dnarep.2004.06.002
   PubMed Web of Science ®Google Scholar
• Jana, D., Halder, A. K., Adhikari, N., Maiti, M. K., Mondal, C., & Jha, T. (2011). Chemometric modeling and pharmacophore mapping in coronary heart disease: 2-arylbenzoxazoles as cholesteryl ester transfer protein inhibitors. Medicinal Chemistry Communication, 2, 840–852. doi:10.1039/C1MD00135C10.1039/c1md00135c
   Web of Science ®Google Scholar
• Jones, P., Altamura, S., Boueres, J. K., Ferrigno, F., Fonsi, M., Giomini, C., … Rowley, M. (2009). Discovery of 2-{4-(3S)-piperadin-3-yl}-2H-indazole-7-carboxamide (MK-4827): A novel oral poly(ADP-ribose)polymerase (PARP) inhibitors efficacious in BRCA-1 and -2 mutant tumors. Journal of Medicinal Chemistry, 52, 7170–7185. doi:10.1021/jm901188v10.1021/jm901188v
   PubMed Web of Science ®Google Scholar
• Lewis, R. A., & Wood, D. (in press). Modern 2D QSAR for drug discovery. WIRES Computational Molecular Science. doi:10.1002/wcms.1187
   Google Scholar
• Ligprep. (2013). Version 2.8. New York, NY: Schrodinger, LLC.
   Google Scholar
• Lyne, P. D., Lamb, M. L., & Saeh, J. C. (2006). Accurate prediction of the relative potencies of members of a series of Kinase inhibitors using molecular docking and MM-GBSA scoring. Journal of Medicinal Chemistry, 49, 4805–4808. doi:10.1021/jm060522a10.1021/jm060522a
   PubMed Web of Science ®Google Scholar
• Mandir, A. S., Poitras, M. F., Berliner, A. R., Herring, W. J., Guastella, D. B., Feldman, A., … Dawson, V. L. (2000). NMDA but not non-NMDA excitotoxicity is mediated by poly(ADP-ribose) polymerase. The Journal of Neuroscience, 20, 8005–8011.
   PubMed Web of Science ®Google Scholar
• McCabe, N., Turner, N. C., Lord, C. J., Klezek, K., Bialkowska, A., Swift, S., … Ashworth, A. (2006). Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-Ribose) polymerase inhibition. Cancer Research, 66, 8109–8115. doi:10.1158/0008-5472.CAN-06-014010.1158/0008-5472.CAN-06-0140
   PubMed Web of Science ®Google Scholar
• Ojha, P. K., & Roy, K. (2010). Chemometric modeling, docking and in silico design of triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors as antimalarials. European Journal of Medicinal Chemistry, 45, 4645–4656. doi:10.1016/j.ejmech.2010.07.03410.1016/j.ejmech.2010.07.034
   PubMed Web of Science ®Google Scholar
• Orvieto, F., Branca, D., Giomini, C., Jones, P., Koch, U., Ontoria, J. M., … Mugarlia, E. (2009). Identification of substituted pyrazolo [1,5-a] quinazoline-5(4H)-one as potent poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors. Bioorganic & Medicinal Chemistry Letters, 19, 4196–4200. doi:10.1016/j.bmcl.2009.05.113
   PubMed Web of Science ®Google Scholar
• Osman, F. G., & Douglas, R. H. (2000). Metric for analyzing hit lists and pharmacophores. In F. G. Guner (Ed.), Pharmacophore perception development and use in drug design (pp. 193–210). La Jolla, San Diego, CA: International University Line.
   Google Scholar
• Papeo, G., Casale, E., Montagnoli, A., & Cirla, A. (2014). PARP inhibitors in cancer therapy: An update. Expert Opinion in Therapeutic Patents, 23, 503–514. doi:10.1517/13543776.2013.768615
   Web of Science ®Google Scholar
• Patel, A. G., De Lorenzo, S. B., Flatten, K. S., Poirier, G. G., & Kaufmann, S. H. (2012). Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clinical Cancer Research, 18, 1655–1662. doi:10.1158/1078-0432.CCR-11-289010.1158/1078-0432.CCR-11-2890
   PubMed Web of Science ®Google Scholar
• Pecorino, L. (2012). Molecular biology of cancer. Oxford: Oxford University Press.
   Google Scholar
• Penning, T. D., Zhu, G. D., Gong, J., Thomas, S., Gandhi, V. B., Liu, X., … Giranda, V. L. (2010). Optimization of phenyl-substituted benzimidazole carboxamide poly(ADP-ribose) polymerase inhibitors: Identification of (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a highly potent and efficacious inhibitor. Journal of Medicinal Chemistry, 53, 3142–3153. doi:10.1021/jm901775y10.1021/jm901775y
   PubMed Web of Science ®Google Scholar
• Pescatore, G., Branca, D., Fiore, F., Kinzel, O., Bufi, L. L., Muraglia, E., … Jones, P. (2010). Identification and SAR of novel pyrrolo[1,2-a]pyrazin-1(2H)-one derivatives as inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1). Bioorganic & Medicinal Chemistry Letters, 20, 1094–1099. doi:10.1016/j.bmcl.2009.12.026
   PubMed Web of Science ®Google Scholar
• Piepar, A. A., Wallaws, T., Wei, G., Clements, E. E., Verma, A., Snyder, S. H., & Zweier, G. L. (2000). Myocardial postischemic injury is reduced by poly(ADP-ribose) polymerase-1 gene disruption. Molecular Medicine, 6, 271–282.
   PubMed Web of Science ®Google Scholar
• Pradhan, D., Priyadarshini, V., Munikumar, M., Swargam, S., Umamaheswari, A., & Bitla, A. (2014). Para-(benzoyl)-phenylalanine as a potential inhibitor against LpxC of Leptospira spp.: Homology modeling, docking, and molecular dynamic study. Journal of Biomolecular Structure & Dynamics, 32, 171–185. doi:10.1080/07391102.2012.758056
   PubMed Web of Science ®Google Scholar
• Prime. (2013). Version 3.3. New York, NY: Schrödinger, LLC.
   Google Scholar
• Ruf, A., Rolli, V., de Murcia, G., & Schulz, G. E. (1998). The mechanism of the elongation and branching reaction of poly(ADP-ribose) polymerase as derived from crystal structures and mutagenesis. Journal of Molecular Biology, 278, 57–65. doi:10.1006/jmbi.1998.167310.1006/jmbi.1998.1673
   PubMed Web of Science ®Google Scholar
• Scarpelli, R., Boueres, J. K., Cerretani, M., Ferrigno, F., Ontoria, J. M., … Jones, P. (2010). Synthesis and biological evaluation of substituted 2-phenyl-2H-indazole-7-carboxamides as potent poly(ADP-ribose) polymerase (PARP) inhibitors. Bioorganic & Medicinal Chemistry Letters, 20, 488–492. doi:10.1016/j.bmcl.2009.11.127
   PubMed Web of Science ®Google Scholar
• SiteMap. (2013). Version 2.9. New York, NY: Schrödinger, LLC.
   Google Scholar
• Stanton, D. T., & Jurs, P. C. (1990). Development and use of charge partial surface area structural descriptors in computer-assisted quantitative structure–property relationship studies. Anaytical Chemistry, 62, 2323–2329. doi:10.1021/ac00220a01310.1021/ac00220a013
   Web of Science ®Google Scholar
• Tentori, L., Portarena, I., & Graziani, G. (2002). Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors. Pharmacology Research, 45, 73–85. doi:10.1006/phrs.2001.093510.1006/phrs.2001.0935
   Web of Science ®Google Scholar
• Todeschini, R., & Consonni, V. (2000). Handbook of molecular descriptors. Weinheim: Wiley-VCH.10.1002/SERIES6138
   Google Scholar
• Torrisi, C., Bisbocci, M., Ingenito, R., Ontoria, J. M., Rowley, M., Schultz-Fademrecht, C., …, Jones, M. (2010). Discovery and SAR of novel, potent and selective hexahydro-benzonaphthyridinone inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1). Bioorganic & Medicinal Chemistry Letters, 20, 448–452. doi:10.1016/j.bmcl.2009.12.002
   PubMed Web of Science ®Google Scholar
• Triballeau, N., Acher, F., Brabet, I., Pin, I.-J., & Bertrand, H. O. (2005). Virtual screening workflow development guided by the ‘receiver operating characteristics’ curve approach application to high-throughput docking on metabotropic glutamate receptor subtype 4. Journal of Medicinal Chemistry, 48, 2534–2547. doi:10.1021/jm049092j10.1021/jm049092j
   PubMed Web of Science ®Google Scholar
• Tripathi, S. K., Muttineni, R., & Singh, S. K. (2013). Extra precision docking, free energy calculation and molecular dynamics simulation studies of CDK2 inhibitors. Journal of Theoretical Biology, 334, 87–100. doi:10.1016/j.jtbi.2013.05.01410.1016/j.jtbi.2013.05.014
   PubMed Web of Science ®Google Scholar
• Walker, J. D., Jaworska, J., Comber, M. H., Schultz, T. W., & Dearden, J. C. (2003). Guidelines for developing and using quantitative structure–activity relationships. Environmental Toxicology and Chemistry, 22, 1653–1665. doi:10.1897/01-62710.1897/01-627
   PubMed Web of Science ®Google Scholar
• Yang, Y., Qin, J., Liu, H., & Yao, X. (2011). Molecular dynamics simulation, free energy calculation and structure-based 3D-QSAR studies of B-RAF kinase inhibitors. Journal of Chemical Information and Modeling, 51, 680–692. doi:10.1021/ci100427j10.1021/ci100427j
   PubMed Web of Science ®Google Scholar
• Ye, N., Chen, C. H., Chen, T., Song, Z., He, J. X., Chen, Y., … Zhang, A. (2013). Design, synthesis, and biological evaluation of a series of Benzo[de][1,7]naphthyridin-7(8H)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors. Journal of Medicinal Chemistry, 56, 2885–2903. doi:10.1021/jm301825t10.1021/jm301825t
   PubMed Web of Science ®Google Scholar
• Zeng, H., Zhang, H., Jang, F., Zhao, L., & Zhang, J. (2011). Molecular modeling studies on benzimidazole carboxamide derivatives as PARP-1 inhibitors using 3D QSAR and docking. Chemical Biology & Drug Design, 78, 333–352. doi:10.1111/j.1747-0285.2011.11139.x
   PubMed Web of Science ®Google Scholar
• Zhu, G.-D., Gandhi, V. B., Gong, J., Thomas, S., Luo, Y., Liu, X., … Penning, T. D. (2008). Synthesis and SAR of novel, potent and orally bioavailable benzimidazole inhibitors of poly(ADP-ribose) polemerase (PARP) with quaternary methylene-amino substituent. Bioorganic & Medicinal Chemistry Letters, 18, 3955–3958. doi:10.1016/j.bmcl.2008.06.023
   PubMed Web of Science ®Google Scholar